Self-Administered Biologics Market Report 2026

The self-administered biologics market size has grown strongly in recent years. It will grow from $95.58 billion in 2025 to $103.23 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increasing biologics drug approvals, growth in hospital-based infusion therapies, limited patient convenience in clinical administration, high healthcare facility burden.

The self-administered biologics market size is expected to see strong growth in the next few years. It will grow to $141.7 billion by 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to expansion of homecare healthcare delivery models, increasing adoption of self-injection devices, growth in biosimilar pipeline expansion, rising patient preference for independence in treatment, advancements in subcutaneous biologic formulations. Major trends in the forecast period include growth of home-based biologic self-administration therapies, rising adoption of patient-centric chronic disease management models, increasing use of prefilled syringes and autoinjectors for ease of dosing, expansion of biosimilar self-injectable therapies in autoimmune and metabolic diseases, improving regulatory approvals and reimbursement support for home-use biologics.

The increasing prevalence of autoimmune disorders is expected to propel the growth of the self-administered biologics market going forward. Autoimmune disorders refer to a category of conditions in which the immune system incorrectly attacks the body’s healthy cells, tissues, or organs, including rheumatoid arthritis (RA), lupus, and multiple sclerosis. The increasing prevalence of autoimmune disorders is mainly attributed to changing lifestyles that affect and disrupt the normal functioning of the immune system. Self-administered biologics assist in managing autoimmune disorders by allowing patients to conveniently administer targeted therapies that regulate immune responses, decrease inflammation, and enhance long-term disease management. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, 212,136 males and 362,137 females are expected to have rheumatoid arthritis (RA) in 2025, with these figures projected to increase to nearly 280,040 males and 479,828 females by 2040. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the self-administered biologics market.

Leading companies operating in the self-administered biologics market are focusing on developing technologically advanced solutions, such as wearable injector technologies, to improve patient convenience and support efficient at-home delivery of complex biologic therapies. Wearable injector technologies are drug delivery devices that attach to the body and automatically administer precise doses of medications, particularly biologics, over a defined period without requiring manual injection. For instance, in July 2025, Becton, Dickinson and Company announced the first pharma-sponsored clinical trial using its BD Libertas Wearable Injector, an advanced drug delivery technology developed to administer high-viscosity biologic drugs in volumes greater than standard autoinjectors, enabling patients to self-administer treatments at home with minimal discomfort. It features a lightweight, on-body design with a simple activation mechanism, supporting ease of use and improved patient compliance. The system incorporates accurate flow rate control and safety mechanisms to ensure precise dosing and minimize the risk of administration errors. Additionally, it supports a broad range of biologic formulations, making it suitable for treating chronic conditions such as autoimmune disorders. This technology helps minimize the need for hospital visits while enhancing patient convenience and healthcare efficiency.

In November 2025, Halozyme Therapeutics, Inc. acquired Elektrofi, Inc. for an undisclosed amount. Through this acquisition, Halozyme aims to broaden its drug delivery capabilities by integrating Elektrofi’s high-concentration biologic injection technology, enabling subcutaneous and self-administered biologic therapies. Elektrofi Inc. is a US-based company focused on developing technology that supports the at-home, self-administration of biologic therapies.

Major companies operating in the self-administered biologics market are Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck And Co Inc., Pfizer Inc., AbbVie Inc., Sanofi S. A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S. A., Genentech Inc., Wockhardt Limited, Gan And Lee Pharmaceuticals Co Ltd., The United Laboratories International Holdings Limited, Tonghua Dongbao Pharmaceutical Co Ltd.

North America was the largest region in the self-administered biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the self-administered biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the self-administered biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Self-administered biologics market consists of sales of prefilled syringes, auto-injectors, pen injectors, wearable injectors, and self-injection kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.